A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering

The clinical use of anti-EGFR antibody-based cancer therapy has been limited by antibody-EGFR binding in normal tissues, so developing pH-dependent anti-EGFR antibodies that selectively bind with EGFR in tumors—by taking advantage of the acidity of tumor microenvironment relative to normal tissues—m...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ximing, Tian, Xinxin, Hao, Xinyan, Zhang, Huixiang, Wang, Kailun, Wei, Zhizhong, Wei, Xin, Li, Yulu, Sui, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703009/
https://www.ncbi.nlm.nih.gov/pubmed/36458200
http://dx.doi.org/10.1016/j.omto.2022.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703009/
https://www.ncbi.nlm.nih.gov/pubmed/36458200
http://dx.doi.org/10.1016/j.omto.2022.11.001

Ejemplares similares